MD20160136A2 - Compuşi dihidroizochinolinonici substituiţi - Google Patents
Compuşi dihidroizochinolinonici substituiţi Download PDFInfo
- Publication number
- MD20160136A2 MD20160136A2 MDA20160136A MD20160136A MD20160136A2 MD 20160136 A2 MD20160136 A2 MD 20160136A2 MD A20160136 A MDA20160136 A MD A20160136A MD 20160136 A MD20160136 A MD 20160136A MD 20160136 A2 MD20160136 A2 MD 20160136A2
- Authority
- MD
- Moldova
- Prior art keywords
- compounds
- salts
- substituted
- substituted dihydroisoquinolinone
- dihydroisoquinolinone compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
Abstract
Invenţia se referă la compuşii cu formula generală (I)(I),şi sărurile farmaceutic acceptabile ale acestora, în care R1, R2, R3, R4, L, X şi Z sunt definite în descriere, la compoziţiile farmaceutice ce conţin asemenea compuşi şi săruri şi la metode de utilizare a acestor compuşi, săruri şi compoziţii pentru tratamentul creşterii anormale a celulelor, inclusiv a cancerului.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462013410P | 2014-06-17 | 2014-06-17 | |
| US201562156533P | 2015-05-04 | 2015-05-04 | |
| PCT/IB2015/054272 WO2015193765A1 (en) | 2014-06-17 | 2015-06-05 | Substituted dihydroisoquinolinone compounds |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| MD20160136A2 true MD20160136A2 (ro) | 2017-05-31 |
| MD4820B1 MD4820B1 (ro) | 2022-08-31 |
| MD4820C1 MD4820C1 (ro) | 2023-03-31 |
Family
ID=53434412
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MDA20160136A MD4820C1 (ro) | 2014-06-17 | 2015-06-05 | Compuşi dihidroizochinolinonici substituiţi |
Country Status (40)
| Country | Link |
|---|---|
| US (4) | US9481666B2 (ro) |
| EP (2) | EP3157915B1 (ro) |
| JP (1) | JP6152495B1 (ro) |
| KR (1) | KR101877187B1 (ro) |
| CN (1) | CN107207464B (ro) |
| AP (1) | AP2016009605A0 (ro) |
| AU (1) | AU2015275826B2 (ro) |
| BR (1) | BR112016029612B1 (ro) |
| CA (1) | CA2894298C (ro) |
| CL (1) | CL2016003246A1 (ro) |
| CR (2) | CR20200484A (ro) |
| CU (1) | CU24408B1 (ro) |
| CY (1) | CY1121706T1 (ro) |
| DK (1) | DK3157915T3 (ro) |
| EA (1) | EA031892B1 (ro) |
| ES (1) | ES2721031T3 (ro) |
| GE (2) | GEP20186933B (ro) |
| HR (1) | HRP20190604T1 (ro) |
| HU (1) | HUE042964T2 (ro) |
| IL (1) | IL248991B (ro) |
| LT (1) | LT3157915T (ro) |
| MA (1) | MA40225B1 (ro) |
| MD (1) | MD4820C1 (ro) |
| ME (1) | ME03419B (ro) |
| MX (1) | MX2016016764A (ro) |
| MY (1) | MY185765A (ro) |
| NZ (1) | NZ726108A (ro) |
| PE (1) | PE20161552A1 (ro) |
| PH (1) | PH12016502378A1 (ro) |
| PL (1) | PL3157915T3 (ro) |
| PT (1) | PT3157915T (ro) |
| RS (1) | RS58632B1 (ro) |
| SG (1) | SG11201609386YA (ro) |
| SI (1) | SI3157915T1 (ro) |
| SV (1) | SV2016005333A (ro) |
| TN (1) | TN2016000529A1 (ro) |
| TW (1) | TWI561516B (ro) |
| UA (1) | UA118380C2 (ro) |
| UY (1) | UY36170A (ro) |
| WO (1) | WO2015193765A1 (ro) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA111305C2 (uk) | 2012-12-21 | 2016-04-11 | Пфайзер Інк. | Конденсовані лактами арилу та гетероарилу |
| EP3157915B1 (en) | 2014-06-17 | 2019-02-27 | Pfizer Inc | Substituted dihydroisoquinolinone compounds |
| UY36758A (es) * | 2015-06-30 | 2016-12-30 | Glaxosmithkline Ip No 2 Ltd | Inhibidores del potenciador del homólogo zeste 2 |
| TW201718598A (zh) | 2015-08-27 | 2017-06-01 | 美國禮來大藥廠 | Ｅｚｈ２抑制劑 |
| CA3023157A1 (en) | 2016-05-05 | 2017-11-09 | Glaxosmithkline Intellectual Property (No.2) Limited | Enhancer of zeste homolog 2 inhibitors |
| WO2018119142A1 (en) | 2016-12-21 | 2018-06-28 | Amgen Inc. | Anti-tnf alpha antibody formulations |
| US10266542B2 (en) | 2017-03-15 | 2019-04-23 | Mirati Therapeutics, Inc. | EZH2 inhibitors |
| US20210147381A1 (en) | 2017-07-17 | 2021-05-20 | AbbVie Deutschland GmbH & Co. KG | 1,2,3,4-substituted quinoline compounds as sip modulators |
| KR20200088386A (ko) | 2017-11-14 | 2020-07-22 | 화이자 인코포레이티드 | Ezh2 억제제 병용 요법 |
| DK3746446T3 (da) | 2018-01-31 | 2022-06-27 | Mirati Therapeutics Inc | PRC2-inhibitorer |
| CR20200553A (es) | 2018-04-18 | 2021-04-08 | Constellation Pharmaceuticals Inc | Moduladores de enzimas modificadoras de metilo, composiciones y usos de estos |
| CN120097995A (zh) * | 2018-05-21 | 2025-06-06 | 星座制药公司 | 甲基修饰酶的调节剂、其组合物和用途 |
| CA3104209A1 (en) | 2018-07-09 | 2020-01-16 | Fondation Asile Des Aveugles | Inhibition of prc2 subunits to treat eye disorders |
| EP3870173A4 (en) * | 2018-10-24 | 2022-06-22 | Vanderbilt University | WDR5 INHIBITORS AND MODULATORS |
| KR102689665B1 (ko) * | 2019-02-19 | 2024-07-31 | 한미약품 주식회사 | 신규한 헤테로트리시클릭 유도체 화합물 및 이의 용도 |
| US12421228B2 (en) | 2019-04-22 | 2025-09-23 | Mirati Therapeutics, Inc. | Naphthyridine derivatives as PRC2 inhibitors |
| US12577227B2 (en) | 2019-06-04 | 2026-03-17 | Vanderbilt University | WDR5 inhibitors and modulators |
| US12252493B2 (en) | 2019-06-05 | 2025-03-18 | Mirati Therapeutics, Inc. | Imidazo[1,2-c]pyrimidine derivatives as PRC2 inhibitors for treating cancer |
| WO2021016414A1 (en) | 2019-07-24 | 2021-01-28 | Constellation Pharmaceuticals, Inc. | Crystalline forms of 7-chloro-2-(4-(3-methoxyazetidin-1-yl)cyclohexyl)-2,4-dimethyl-n-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)benzo[d][1,3]dioxole-5-carboxamide |
| WO2022018594A1 (en) | 2020-07-20 | 2022-01-27 | Pfizer Inc. | Synthesis of novel intermediates for substituted 3,4-dihydroisoquinolinones |
| AR123185A1 (es) | 2020-08-10 | 2022-11-09 | Novartis Ag | Compuestos y composiciones para inhibir ezh2 |
| MX2023001603A (es) * | 2020-08-13 | 2023-03-07 | Hanmi Pharmaceutical Co Ltd | Derivados de dioxoloisoquinolinona novedosos y uso de los mismos. |
| EP4261211A4 (en) * | 2020-12-11 | 2024-12-25 | Etern Biopharma (Shanghai) Co., Ltd. | DIHYDROISOQUINOLINONE DERIVATIVE AND ITS APPLICATION |
| CN118302427A (zh) * | 2021-12-02 | 2024-07-05 | 上海翰森生物医药科技有限公司 | 稠环类衍生物调节剂、其制备方法和应用 |
| WO2023111810A1 (en) | 2021-12-14 | 2023-06-22 | Pfizer Inc. | Combination therapies and uses for treating cancer |
| CN116239519A (zh) * | 2023-02-20 | 2023-06-09 | 安徽峆一药业股份有限公司 | 一种(2-苄氧基-4,6-二甲基吡啶-3-基)甲醇的合成方法 |
| WO2025064641A1 (en) * | 2023-09-19 | 2025-03-27 | Sri International | Synthetic compounds comprising dihydroisoquinolinone monomers |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3846412A (en) | 1971-03-18 | 1974-11-05 | Lepetit Spa | Dihydro-2-amino-isoquinolines and their derivatives |
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| GB9518953D0 (en) | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
| WO2000035298A1 (en) | 1996-11-27 | 2000-06-22 | Wm. Wrigley Jr. Company | Chewing gum containing medicament active agents |
| GB9711643D0 (en) | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
| FR2889526B1 (fr) | 2005-08-04 | 2012-02-17 | Aventis Pharma Sa | 7-aza-indazoles substitues, compositions les contenant, procede de fabrication et utilisation |
| AU2006279548A1 (en) | 2005-08-16 | 2007-02-22 | Amgen, Inc. | Phosphodiesterase 10 inhibitors |
| WO2007075783A2 (en) * | 2005-12-22 | 2007-07-05 | Wyeth | Substituted isoquinoline-1,3(2h,4h)-diones, 1-thioxo-1,4-dihydro-2h-isoquinoline-3-ones and 1,4-dihydro-3(2h)-isoquinolones and use thereof as kinase inhibitor |
| US20100113415A1 (en) | 2008-05-29 | 2010-05-06 | Rajapakse Hemaka A | Epha4 rtk inhibitors for treatment of neurological and neurodegenerative disorders and cancer |
| MX2010014057A (es) * | 2008-06-17 | 2011-03-21 | Astrazeneca Ab | Compuestos de piridina. |
| US8440693B2 (en) * | 2009-12-22 | 2013-05-14 | Novartis Ag | Substituted isoquinolinones and quinazolinones |
| WO2011103016A2 (en) | 2010-02-19 | 2011-08-25 | The Regents Of The University Of Michigan | Compositions and methods for inhibiting ezh2 |
| US8846935B2 (en) | 2010-05-07 | 2014-09-30 | Glaxosmithkline Llc | Indazoles |
| UA110112C2 (uk) | 2010-05-07 | 2015-11-25 | Глаксосмітклайн Ллс | Індоли |
| JP5889875B2 (ja) | 2010-05-07 | 2016-03-22 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ | アザインダゾール |
| BR112013005806B1 (pt) | 2010-09-10 | 2022-05-10 | Epizyme, Inc | Métodos para detectar se um indivíduo é um candidato para o tratamento com ou responsivo a um inibidor de ezh2 e usos terapêuticos do dito inibidor de ezh2 |
| US8946260B2 (en) | 2010-09-16 | 2015-02-03 | Novartis Ag | 17α-hydroxylase/C17,20-lyase inhibitors |
| US20130310379A1 (en) | 2010-11-19 | 2013-11-21 | Constellation Pharmaceuticals | Modulators of methyl modifying enzymes, compositions and uses thereof |
| ES2951688T3 (es) | 2011-02-28 | 2023-10-24 | Epizyme Inc | Compuestos de heteroarilo biciclico fusionados en 6,5 sustituidos |
| JO3363B1 (ar) | 2011-04-13 | 2019-03-13 | Epizyme Inc | مركبات بنزين مستبدلة بأريل أو أريل غير متجانس |
| TWI598336B (zh) * | 2011-04-13 | 2017-09-11 | 雅酶股份有限公司 | 經取代之苯化合物 |
| CA2850570A1 (en) | 2011-09-30 | 2013-04-04 | Glaxosmithkline Llc | Methods of treating cancer |
| WO2013059944A1 (en) * | 2011-10-28 | 2013-05-02 | British Columbia Cancer Agency Branch | Epigenetic regulators and uses thereof |
| WO2013173441A2 (en) | 2012-05-16 | 2013-11-21 | Glaxosmithkline Llc | Enhancer of zeste homolog 2 inhibitors |
| JP6254169B2 (ja) | 2012-09-28 | 2017-12-27 | ファイザー・インク | ベンズアミドおよびヘテロベンズアミド化合物 |
| EP2935312B1 (en) | 2012-12-21 | 2018-08-08 | F.Hoffmann-La Roche Ag | Peptides as oxytocin agonists |
| UA111305C2 (uk) | 2012-12-21 | 2016-04-11 | Пфайзер Інк. | Конденсовані лактами арилу та гетероарилу |
| FR3000065A1 (fr) | 2012-12-21 | 2014-06-27 | Univ Lille Ii Droit & Sante | Composes bicycliques ayant une activite potentialisatrice de l'activite d'un antibiotique actif contre les mycobacteries-composition et produit pharmaceutiques comprenant de tels composes |
| UA118548C2 (uk) | 2012-12-21 | 2019-02-11 | Епізайм, Інк. | Тетрагідро- та дигідроізохіноліни як інгібітори prmt5 та їх застосування |
| HK1211232A1 (en) | 2012-12-21 | 2016-05-20 | Sanofi | Exendin-4 derivatives as dual glp1/gip or trigonal glp1/gip/glucagon agonists |
| US9233974B2 (en) | 2012-12-21 | 2016-01-12 | Gilead Sciences, Inc. | Antiviral compounds |
| FR3000059A1 (fr) | 2012-12-21 | 2014-06-27 | Saint Gobain Placo | Composition pour plaques de platre et produits obtenus |
| EA030003B1 (ru) | 2012-12-21 | 2018-06-29 | Джилид Сайэнс, Инк. | Полициклическое карбамоилпиридоновое соединение и его фармацевтическое применение для лечения вич-инфекции |
| GEP201706757B (en) | 2012-12-21 | 2017-10-25 | Alios Biopharma Inc | Substituted nucleosides, nucleotides and analogs thereof |
| EP2935248B1 (en) | 2012-12-21 | 2018-02-28 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
| EP3157915B1 (en) | 2014-06-17 | 2019-02-27 | Pfizer Inc | Substituted dihydroisoquinolinone compounds |
-
2015
- 2015-06-05 EP EP15730290.2A patent/EP3157915B1/en active Active
- 2015-06-05 MA MA40225A patent/MA40225B1/fr unknown
- 2015-06-05 JP JP2016573051A patent/JP6152495B1/ja active Active
- 2015-06-05 ES ES15730290T patent/ES2721031T3/es active Active
- 2015-06-05 NZ NZ726108A patent/NZ726108A/en unknown
- 2015-06-05 CN CN201580032058.7A patent/CN107207464B/zh active Active
- 2015-06-05 SI SI201530698T patent/SI3157915T1/sl unknown
- 2015-06-05 CU CU2016000180A patent/CU24408B1/es unknown
- 2015-06-05 SG SG11201609386YA patent/SG11201609386YA/en unknown
- 2015-06-05 BR BR112016029612-5A patent/BR112016029612B1/pt active IP Right Grant
- 2015-06-05 GE GEAP201514347A patent/GEP20186933B/en unknown
- 2015-06-05 ME MEP-2019-85A patent/ME03419B/me unknown
- 2015-06-05 LT LTEP15730290.2T patent/LT3157915T/lt unknown
- 2015-06-05 PT PT15730290T patent/PT3157915T/pt unknown
- 2015-06-05 TN TN2016000529A patent/TN2016000529A1/en unknown
- 2015-06-05 EP EP19159058.7A patent/EP3521285A1/en not_active Withdrawn
- 2015-06-05 MY MYPI2016704453A patent/MY185765A/en unknown
- 2015-06-05 CR CR20200484A patent/CR20200484A/es unknown
- 2015-06-05 KR KR1020177001230A patent/KR101877187B1/ko active Active
- 2015-06-05 MX MX2016016764A patent/MX2016016764A/es active IP Right Grant
- 2015-06-05 GE GEAP201814347A patent/GEAP201814347A/en unknown
- 2015-06-05 HR HRP20190604TT patent/HRP20190604T1/hr unknown
- 2015-06-05 CR CR20160574A patent/CR20160574A/es unknown
- 2015-06-05 AP AP2016009605A patent/AP2016009605A0/en unknown
- 2015-06-05 MD MDA20160136A patent/MD4820C1/ro active IP Right Grant
- 2015-06-05 RS RS20190512A patent/RS58632B1/sr unknown
- 2015-06-05 UA UAA201611695A patent/UA118380C2/uk unknown
- 2015-06-05 DK DK15730290.2T patent/DK3157915T3/en active
- 2015-06-05 EA EA201692114A patent/EA031892B1/ru unknown
- 2015-06-05 WO PCT/IB2015/054272 patent/WO2015193765A1/en not_active Ceased
- 2015-06-05 AU AU2015275826A patent/AU2015275826B2/en active Active
- 2015-06-05 PL PL15730290T patent/PL3157915T3/pl unknown
- 2015-06-05 PE PE2016002737A patent/PE20161552A1/es unknown
- 2015-06-05 HU HUE15730290A patent/HUE042964T2/hu unknown
- 2015-06-15 TW TW104119287A patent/TWI561516B/zh active
- 2015-06-16 US US14/740,439 patent/US9481666B2/en active Active
- 2015-06-16 CA CA2894298A patent/CA2894298C/en active Active
- 2015-06-16 UY UY0001036170A patent/UY36170A/es not_active Application Discontinuation
-
2016
- 2016-09-12 US US15/262,230 patent/US20160376254A1/en not_active Abandoned
- 2016-11-15 IL IL248991A patent/IL248991B/en active IP Right Grant
- 2016-11-29 PH PH12016502378A patent/PH12016502378A1/en unknown
- 2016-12-05 SV SV2016005333A patent/SV2016005333A/es unknown
- 2016-12-19 CL CL2016003246A patent/CL2016003246A1/es unknown
-
2017
- 2017-06-28 US US15/635,648 patent/US20170298048A1/en not_active Abandoned
-
2018
- 2018-10-10 US US16/156,304 patent/US10570121B2/en active Active
-
2019
- 2019-04-05 CY CY20191100381T patent/CY1121706T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12016502378A1 (en) | Substituted dihydroisoquinolinone compounds | |
| MX389597B (es) | Inhibidores de cdk2/4/6 de piridopirimidinona. | |
| TN2015000281A1 (fr) | Lactames condenses aryliques et heteroaryliques | |
| MD4800B1 (ro) | Compuşi de aminopirimidinil ca inhibitori de JAK | |
| MX2017008518A (es) | Compuestos de isoquinolina para el tratamiento de virus de inmunodeficiencia humana (vih). | |
| MD4650B1 (ro) | Derivaţi de chinazolină utilizaţi în tratamentul HIV | |
| MA39986A (fr) | Dérivés de purine en tant qu'inhibiteurs de cd73 pour le traitement du cancer | |
| PH12018500061A1 (en) | Oxysterols and methods of use thereof | |
| TW201613864A (en) | Novel compounds | |
| PH12017501539A1 (en) | Disacetoxytubulysin h and analogs thereof | |
| PH12017500089A1 (en) | Aldosterone synthase inhibitors | |
| PH12017500595A1 (en) | Aldosterone synthase inhibitors | |
| PH12016501997A1 (en) | Cycloalkyl-linked diheterocycle derivatives | |
| PH12015500399A1 (en) | Azaindolines | |
| PH12017501147A1 (en) | Total synthesis of trioxacarcin dc-45-a2 and preparation of trioxacarcin analogs |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG4A | Patent for invention issued |